RAC — Rithm Acquisition Corp.

Rite Aid Corporation (RAC) Q1 2024 Earnings Call Summary

1. Key Financial Results and Metrics:

• Adjusted EBITDA: $91.7 million, down from $100.1 million year-over-year.
• Net Loss: $306.7 million ($5.56 per share), with an adjusted net loss of $40.1 million ($0.73 per share).
• Goodwill Impairment: $152 million charge related to Elixir.
• Revenues: Retail Pharmacy segment revenues increased by 3.4%, while Elixir revenues decreased by 30% year-over-year to $1.2 billion.
• Same Store Sales: Increased by 8.4% overall, with a 13.3% rise in pharmacy sales but a 4.4% decline in front-end sales.
• Script Growth: 4.7% increase in same-store prescriptions, 7.4% excluding COVID impacts.

2. Strategic Updates and Business Highlights:

• Pharmacy Initiatives: Strong adherence initiatives led to a 10.3% increase in courtesy refills. A pilot program to reduce abandoned scripts is being rolled out across all stores.
• Elixir Insurance: The company plans to exit the individual Medicare Part D market due to adverse selection and a higher-than-expected medical loss ratio.
• Front-End Sales Strategy: Focus on improving product assortment and pricing strategies, with an emphasis on launching new owned brands.
• Shrink Management: New leadership in loss prevention to address ongoing shrink issues, which negatively impacted profits by $9 million compared to the previous year.

3. Forward Guidance and Outlook:

• Adjusted EBITDA Guidance: Elixir's adjusted EBITDA is now expected to be between $90 million and $100 million, while retail EBITDA guidance remains at $240 million to $260 million.
• Total Revenue Guidance: Expected to be between $22.6 billion and $23 billion, adjusted upwards due to increased sales of high-dollar GLP-1 drugs.
• Capital Expenditure: Guidance lowered to $175 million, with expectations of cash use between $100 million and $150 million for the fiscal year.
• Second Half Performance: Anticipated to generate approximately 60% of adjusted EBITDA for the year in the second half.

4. Bad News, Challenges, or Points of Concern:

• Medical Loss Ratio: Higher than expected at Elixir, leading to a downward revision in profitability expectations.
• Front-End Sales Decline: Comp store transactions down 7.9%, attributed to reduced demand for respiratory products and supply chain challenges.
• Store Closures: Continued evaluation of store performance may lead to further closures, impacting overall presence and sales.
• Debt Maturities: Ongoing discussions with lenders regarding 2025 debt maturities without a specific update on outcomes.

5. Notable Q&A Insights:

• COVID Impact: Significant drop in COVID vaccine administration, with only 500,000 vaccines compared to 1.7 million in the previous year.
• Kroger Dispute: No specific quantification of impact from the Kroger dispute, but the company is capturing its fair share of volume.
• Shrink Issues: Ongoing challenges with shrink, with new strategies being implemented to mitigate losses.
• Elixir Membership: Approximately 300,000 lives will be lost due to exiting the individual Medicare Part D market, which is not profitable.
• Market Position: Positive feedback received during the early selling season for Elixir, but still too early to project outcomes.

This summary encapsulates the key aspects of Rite Aid's Q1 2024 earnings call, highlighting both the challenges faced and the strategic initiatives in place to drive future growth.